Actionable news
All posts from Actionable news
Actionable news in SGEN: Seattle Genetics, Inc.,

Seattle Genetics initiates study of ADCETRIS/Opdivo in HL

Seattle Genetics (NASDAQ:SGEN) commences a Phase 1/2 clinical trial evaluating the combination of ADCETRIS (brentuximab vedotin) and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in patients with relapsed/refractory Hodgkin lymphoma (HL) who have failed first-line treatment. The trial, which will enroll ~60 subjects, is being conducted to see if patient outcomes...